ep figur prior figur
revenu figur prior figur
 add benefit keytruda
skin cancer downgrad neutral
messag merck report first-lin melanoma
meet co-primari endpoint accord dsmb os also met
data suggest incyt inhibitor provid addit benefit merck io
inhibitor keytruda alon base hazard ratio studi assum probabl
success studi epacadostat zero exclud epacadostat revenu
model drop dcf valuat per share therefor downgrad
stock neutral buy
neutral merck buy report morn
trial first-lin melanoma combin inci epacadostat inhibitor
mrk keytruda pembrolizumab compar keytruda alon demonstr
benefit progress free surviv fact hazard ratio impli epacadostat
benefit ad keytruda dsmb data safeti monitor board
suggest trial stop co-primari endpoint overal surviv also
expect met hazard ratio
program includ clinic trial design compar epacadostat io
inhibitor pembrolizumab nivolumab buy versu io agent
alon differ tumor includ melanoma nsclc bladder cancer renal cell cancer
head neck cancer premis studi driven previou singl arm
trial indic benefit overal respons patient key singl arm studi
patient unresect metastat melanoma placebo arm
keytruda alon given hr one might assum would low probabl
studi tumor type would show benefit therefor model
assum probabl epacadostat reach market
effect
remind comparison epacadostat plu keytruda keytruda
alon increas demand mrk keytruda melanoma base posit
outcom could possibl true posit might
increas demand keytruda melanoma though separ line item
model import data keytruda upcom trial lung cancer known
reveal total upcom scientif meet known
april continu believ previous
state posit respect os increas demand keytruda sale
especi lung cancer therefor rate remain buy remain
downgrad rate buy neutral follow neg result
phase trial evalu epacadostat keytruda exclud
futur epacadostat revenu model trial fail meet
primari endpoint progression-fre surviv hazard ratio second primari
endpoint overal surviv expect reach statist signific addit
previous expect sg increas follow launch
epacadostat melanoma thu decreas sg estim
account epacadostat model
page analyst certif import disclosur
valuat risk
valuat assum growth current jakafi sale ex-u royalti
myelofibrosi polycythemia vera baricitinib sale ra risk-adjust well
iclusig sale valuat base sum discount cash flow use
unchang risk-fre rate termin growth rate market premium wacc
plu net cash
risk near-term risk rate price target includ limit
inci failur execut commerci jakafi unit state
lower expect ex-u jakafi royalti payment longer term key
risk includ unfavor clinical/regulatori outcom jakafi pancreat cancer
baricitinib delay approv risk upsid includ posit data readout
trial evalu ido inhibitor epacadostat higher-than-expect sale
mileston payment key product
page analyst certif import disclosur
thousand except per-shar figur
licens royalti revenu
good sold
research develop
sell gener administr
incom loss oper
incom loss oper
royal taken product royalti revenu line
page analyst certif import disclosur
